Anika Therapeutics (NASDAQ:ANIK) Director John Henneman III Buys 5,000 Shares
by Doug Wharley · The Cerbat GemAnika Therapeutics Inc. (NASDAQ:ANIK – Get Free Report) Director John Henneman III purchased 5,000 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was acquired at an average price of $14.66 per share, with a total value of $73,300.00. Following the purchase, the director directly owned 54,871 shares of the company’s stock, valued at approximately $804,408.86. The trade was a 10.03% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Anika Therapeutics Stock Performance
Shares of ANIK stock traded down $0.11 during mid-day trading on Monday, hitting $14.75. The company’s stock had a trading volume of 33,368 shares, compared to its average volume of 141,579. The stock has a market cap of $196.20 million, a price-to-earnings ratio of -18.66 and a beta of 0.16. Anika Therapeutics Inc. has a 52-week low of $7.87 and a 52-week high of $16.24. The business has a 50-day moving average price of $14.31 and a 200 day moving average price of $11.32.
Anika Therapeutics (NASDAQ:ANIK – Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.34. The company had revenue of $29.61 million during the quarter, compared to analysts’ expectations of $28.14 million. Anika Therapeutics had a negative return on equity of 5.90% and a negative net margin of 9.52%. Equities research analysts predict that Anika Therapeutics Inc. will post -0.61 EPS for the current fiscal year.
Institutional Trading of Anika Therapeutics
Several hedge funds have recently bought and sold shares of ANIK. AQR Capital Management LLC bought a new stake in Anika Therapeutics during the first quarter valued at about $181,000. Cetera Investment Advisers grew its holdings in Anika Therapeutics by 93.1% during the second quarter. Cetera Investment Advisers now owns 19,509 shares of the biotechnology company’s stock valued at $206,000 after purchasing an additional 9,407 shares during the period. American Century Companies Inc. grew its holdings in Anika Therapeutics by 32.8% during the second quarter. American Century Companies Inc. now owns 44,161 shares of the biotechnology company’s stock valued at $467,000 after purchasing an additional 10,909 shares during the period. Marshall Wace LLP bought a new stake in Anika Therapeutics during the second quarter valued at about $241,000. Finally, Jane Street Group LLC grew its holdings in Anika Therapeutics by 31.6% during the second quarter. Jane Street Group LLC now owns 22,871 shares of the biotechnology company’s stock valued at $242,000 after purchasing an additional 5,488 shares during the period. Institutional investors own 91.53% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of analysts recently commented on ANIK shares. Wall Street Zen cut Anika Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Barrington Research upped their price objective on Anika Therapeutics from $16.00 to $17.00 and gave the company an “outperform” rating in a research report on Friday, February 27th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Anika Therapeutics has an average rating of “Hold” and a consensus price target of $17.00.
Read Our Latest Stock Analysis on Anika Therapeutics
Anika Therapeutics Company Profile
Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.
The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.